Patent · US Active

EGFR and C-Met fibronectin type III domain binding molecules

US9725497B2 · kind B2 · utility

2Cited by

9References

13Claims

0Family size

Assignee

JANSSEN BIOTECH, INC. · US

Inventors

Mark Anderson · Norristown, US
Ricardo Attar · Lawrenceville, US
Michael Diem · Havertown, US
Linus Hyun · Radnor, US
Steven Jacobs · North Wales, US
Alastair King · Norristown, US
Donna Klein · Philadelphia, US
Sheri Moores · Phoenixville, US
Karyn O'Neil · Spring House, US
Kristen Picha · Malvern, US

Key dates

Filing date	Nov 21, 2013
Grant date	Aug 8, 2017
Priority date	—
Expiry date	Nov 21, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/70
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.